Free Trial

GRAIL (NASDAQ:GRAL) Stock Price Up 7.2% - Still a Buy?

GRAIL logo with Medical background

Key Points

  • GRAIL, Inc. (NASDAQ:GRAL) saw a significant stock increase of 7.2%, closing at $53.43 after previously trading at $49.86.
  • The company's latest quarterly earnings report indicated a loss of ($3.18) per share, falling short of analysts' expectations, and total revenue of $35.54 million, which was below the projected $37.57 million.
  • Insider trading activity includes CFO and President selling shares, totaling over $17 million in transactions, which reflects a decrease in their ownership stakes in GRAIL.
  • Interested in GRAIL? Here are five stocks we like better.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) shot up 7.2% on Monday . The company traded as high as $52.77 and last traded at $53.43. 203,439 shares traded hands during trading, a decline of 84% from the average session volume of 1,271,020 shares. The stock had previously closed at $49.86.

GRAIL Stock Up 17.9%

The stock has a 50-day simple moving average of $36.33 and a two-hundred day simple moving average of $36.08. The firm has a market cap of $2.12 billion, a PE ratio of -4.48 and a beta of 3.20.

GRAIL (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing analysts' consensus estimates of ($3.14) by ($0.04). The firm had revenue of $35.54 million for the quarter, compared to analysts' expectations of $37.57 million. GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. Research analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Insider Transactions at GRAIL

In other news, CFO Aaron Freidin sold 8,000 shares of GRAIL stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $38.93, for a total value of $311,440.00. Following the transaction, the chief financial officer owned 286,020 shares in the company, valued at approximately $11,134,758.60. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joshua J. Ofman sold 4,202 shares of GRAIL stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $32.02, for a total value of $134,548.04. Following the completion of the transaction, the president owned 487,874 shares in the company, valued at approximately $15,621,725.48. This represents a 0.85% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 352,002 shares of company stock worth $17,276,282.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GRAL. Wealthquest Corp purchased a new position in GRAIL during the 1st quarter valued at about $18,247,000. AQR Capital Management LLC boosted its position in GRAIL by 61.0% during the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company's stock valued at $33,991,000 after acquiring an additional 506,440 shares in the last quarter. Geode Capital Management LLC boosted its position in GRAIL by 60.4% during the 2nd quarter. Geode Capital Management LLC now owns 757,770 shares of the company's stock valued at $38,969,000 after acquiring an additional 285,331 shares in the last quarter. Carnegie Investment Counsel bought a new stake in GRAIL during the 2nd quarter valued at approximately $8,520,000. Finally, Invesco Ltd. boosted its position in GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company's stock valued at $11,244,000 after acquiring an additional 157,780 shares in the last quarter.

About GRAIL

(Get Free Report)

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GRAIL Right Now?

Before you consider GRAIL, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.

While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.